OLGA VALERY VOLPERT

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. pmc Nuclear factor of activated T cells balances angiogenesis activation and inhibition
    Tetiana A Zaichuk
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    J Exp Med 199:1513-22. 2004
  2. pmc miR-200b inhibits prostate cancer EMT, growth and metastasis
    Latanya V Williams
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America
    PLoS ONE 8:e83991. 2013
  3. pmc Androgen receptor drives cellular senescence
    Yelena Mirochnik
    Urology Department, Northwestern University, Chicago, Illinois, United States of America
    PLoS ONE 7:e31052. 2012
  4. pmc PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments
    Dorina Veliceasa
    Urology Department, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
    PPAR Res 2008:945275. 2008
  5. ncbi request reprint Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance
    O V Volpert
    Department of Urology and R H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Metastasis Rev 19:87-92. 2000
  6. ncbi request reprint Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor
    Olga V Volpert
    Department of Urology, Northwestern University Medical School, Chicago, Illinois, USA
    Nat Med 8:349-57. 2002
  7. ncbi request reprint Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer
    Stephanie Filleur
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer Res 65:5144-52. 2005
  8. pmc NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement
    Arin B Aurora
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Blood 116:475-84. 2010
  9. pmc Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth
    Yelena Mirochnik
    Urology Department, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Clin Cancer Res 15:1655-63. 2009
  10. pmc Natural angiogenesis inhibitor signals through Erk5 activation of peroxisome proliferator-activated receptor gamma (PPARgamma)
    Dauren Biyashev
    Urology Department and RH Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Biol Chem 285:13517-24. 2010

Collaborators

Detail Information

Publications23

  1. pmc Nuclear factor of activated T cells balances angiogenesis activation and inhibition
    Tetiana A Zaichuk
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    J Exp Med 199:1513-22. 2004
    ..We propose that one possible mechanism of concerted angiogenesis regulation by activators and inhibitors may be modulation of the endothelial cell apoptosis via c-FLIP controlled by NFAT and its upstream regulator JNK...
  2. pmc miR-200b inhibits prostate cancer EMT, growth and metastasis
    Latanya V Williams
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America
    PLoS ONE 8:e83991. 2013
    ..Our results suggest an important role for miR-200 b in prostate cancer progression and indicate its potential utility for prostate cancer therapy...
  3. pmc Androgen receptor drives cellular senescence
    Yelena Mirochnik
    Urology Department, Northwestern University, Chicago, Illinois, United States of America
    PLoS ONE 7:e31052. 2012
    ..All these pathways contributed to growth arrest, which resolved in senescence due to concomitant lack of p53 and high mTOR activity. This is the first demonstration of senescence response caused by a nuclear hormone receptor...
  4. pmc PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments
    Dorina Veliceasa
    Urology Department, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
    PPAR Res 2008:945275. 2008
    ..Below, we summarize current knowledge of PPARgamma regulatory mechanisms and molecular targets, and discuss ways to maximize the beneficial activity of the PPARgamma agonists...
  5. ncbi request reprint Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance
    O V Volpert
    Department of Urology and R H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Metastasis Rev 19:87-92. 2000
    ..Thus the relative strength of the death and survival signal or signals determines the fate of endothelial cell and therefore the fate of remodeling vessel...
  6. ncbi request reprint Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor
    Olga V Volpert
    Department of Urology, Northwestern University Medical School, Chicago, Illinois, USA
    Nat Med 8:349-57. 2002
    ..This example of cooperation between pro- and anti-angiogenic factors in the inhibition of angiogenesis provides one explanation for the ability of inhibitors to select remodeling capillaries for destruction...
  7. ncbi request reprint Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer
    Stephanie Filleur
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer Res 65:5144-52. 2005
    ..Our results map active regions for the two PEDF functions, signaling via distinct receptors, identify candidate peptides, and provide their mechanism of action for future development of PEDF-based tumor therapies...
  8. pmc NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement
    Arin B Aurora
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Blood 116:475-84. 2010
    ..Our study defines an interactive transcriptional network underlying angiogenic balance and points to HDACi as tools to manipulate the angiogenic switch...
  9. pmc Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth
    Yelena Mirochnik
    Urology Department, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Clin Cancer Res 15:1655-63. 2009
    ..Our previous studies mapped PEDF antiangiogenic and prosurvival activities to distinct epitopes. This study was aimed to determine the minimal fragment of PEDF, which maintains antiangiogenic and antitumor efficacy...
  10. pmc Natural angiogenesis inhibitor signals through Erk5 activation of peroxisome proliferator-activated receptor gamma (PPARgamma)
    Dauren Biyashev
    Urology Department and RH Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Biol Chem 285:13517-24. 2010
    ..This is the first evidence of Erk5-dependent transduction of signals by endogenous angiogenesis inhibitors...
  11. ncbi request reprint Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy
    Ronald Yap
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Clin Cancer Res 11:6678-85. 2005
    ..Thus, our study shows a "complementation" design of an optimal cancer treatment with the antiangiogenic peptide and a metronomic chemotherapy...
  12. pmc Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism
    Norm D Smith
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Urol 179:2427-34. 2008
    ..We report that PEDF induced the neuroendocrine differentiation of prostate cancer cells, which was accompanied by neurite outgrowth and chromogranin A expression...
  13. ncbi request reprint Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma
    Dorina Veliceasa
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    FEBS J 274:6365-77. 2007
    ..Our study indicates that TRPC4 loss in RCC leads to impaired Ca(2+) intake, misfolding, retrograde transport and diminished secretion of antiangiogenic TSP1, thus enabling angiogenic switch during RCC progression...
  14. ncbi request reprint MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis
    Anait S Levenson
    Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer Res 65:10651-6. 2005
    ..Taken together, our results suggest that MCT-1 may contribute to the pathogenesis and progression of human breast cancer via at least two routes: promotion of angiogenesis through the decline of TSP1 and inhibition of apoptosis...
  15. ncbi request reprint Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels
    Susan E Crawford
    Department of Pathology, Children s Memorial Hospital and Institute for Education and Research, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    J Heart Lung Transplant 23:666-73. 2004
    ..We postulated that angiogenic inducers are upregulated post-transplantation and captopril ameliorates transplant coronary artery disease by suppressing the angiogenic activity of coronaries...
  16. ncbi request reprint SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis
    Alexandre Chlenski
    The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Cancer Res 62:7357-63. 2002
    ..SPARC may be an effective candidate for the treatment of children with clinically aggressive, Schwannian stroma-poor NB tumors...
  17. ncbi request reprint Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1
    Olga V Volpert
    Department of Urology and RH Lurie Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Cell 2:473-83. 2002
    ..This decrease was completely reversed by a TSP-1 neutralizing antibody. We conclude that TSP-1 is a major target for Id1 effects on angiogenesis...
  18. ncbi request reprint Alpha1-antitrypsin inhibits angiogenesis and tumor growth
    Hanhua Huang
    Department of Urology and Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Int J Cancer 112:1042-8. 2004
    ..Comparative analysis of the human tumors and normal tissues of origin showed correlation between reduced local alpha(1)-antitrypsin expression and more aggressive tumor growth...
  19. ncbi request reprint Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase
    M Asif Amin
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill, USA
    Circ Res 93:321-9. 2003
    ..Our findings support a role for MIF as an angiogenic factor and provide a rationale for the use of MIF as a therapeutic inducer of neovascularization in the development of collateral circulation in coronary artery disease...
  20. pmc Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells
    Marie Ange Renault
    Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    J Mol Cell Cardiol 49:490-8. 2010
    ..Collectively, our results identify a "nonclassical" pathway by which Shh directly modulates EC phenotype and angiogenic activity...
  21. ncbi request reprint Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics
    Frank K Reiher
    Department of Urology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL, USA
    Int J Cancer 98:682-9. 2002
    ..Such short peptides targeted to a specific antiangiogenic receptor, potent and easy to synthesize, show great promise as lead compounds in clinical antiangiogenic strategies...
  22. ncbi request reprint Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510
    Hanhua Huang
    Department of Urology, Northwestern University Medical School, Chicago, IL 60611, USA
    Mol Cancer Res 2:541-50. 2004
    ..Our data provide one mechanism for the in vivo angioinhibitory effect of PPARgamma ligands and show fine-tuning of the antiangiogenic efficacy via targeted up-regulation of the endothelial receptor...
  23. ncbi request reprint Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1
    Olga V Volpert
    Department of Urology, RH Lurie Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Cell 3:199-200. 2003
    ..2003)...

Research Grants12

  1. Regulation of angiogenic balance by thrombospondin-1.
    Olga Volpert; Fiscal Year: 2009
    ..These studies will yield new targets for therapeutic intervention using natural inhibitors. ..
  2. Regulation of angiogenic balance by thrombospondin-1
    Olga Volpert; Fiscal Year: 2001
    ..This approach has the potential to steer clinical trials towards their most effective use alone, combined with conventional chemotherapy, and for prevention, to delay progressive growth of the dormant tumors. ..
  3. Maximization of anti-angiogenesis by thrombospondin-1
    Olga Volpert; Fiscal Year: 2007
    ..Such combined therapies present a promising new approach to the treatment of cancer and other angiogenesis dependent diseases. ..
  4. Maximization of anti-angiogenesis by thrombospondin-1
    Olga Volpert; Fiscal Year: 2006
    ..Such combined therapies present a promising new approach to the treatment of cancer and other angiogenesis dependent diseases. ..
  5. Regulation of angiogenic balance by thrombospondin-1
    Olga Volpert; Fiscal Year: 2004
    ..This approach has the potential to steer clinical trials towards their most effective use alone, combined with conventional chemotherapy, and for prevention, to delay progressive growth of the dormant tumors. ..
  6. Regulation of angiogenic balance by thrombospondin-1
    Olga Volpert; Fiscal Year: 2003
    ..This approach has the potential to steer clinical trials towards their most effective use alone, combined with conventional chemotherapy, and for prevention, to delay progressive growth of the dormant tumors. ..
  7. Maximization of anti-angiogenesis by thrombospondin-1
    Olga Volpert; Fiscal Year: 2005
    ..Such combined therapies present a promising new approach to the treatment of cancer and other angiogenesis dependent diseases. ..
  8. Regulation of angiogenic balance by thrombospondin-1.
    Olga Volpert; Fiscal Year: 2006
    ..These studies will yield new targets for therapeutic intervention using natural inhibitors. ..
  9. Regulation of angiogenic balance by thrombospondin-1.
    Olga Volpert; Fiscal Year: 2007
    ..These studies will yield new targets for therapeutic intervention using natural inhibitors. ..
  10. Regulation of angiogenic balance by thrombospondin-1
    Olga Volpert; Fiscal Year: 2002
    ..This approach has the potential to steer clinical trials towards their most effective use alone, combined with conventional chemotherapy, and for prevention, to delay progressive growth of the dormant tumors. ..